Physician profile
Jason Schmit
NPI 1124220322
$78,746.49
in general payments reported to CMS, 2019-2025
25 companies · $463 in 2025
The $463 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $1,310 · 2021: $15K · 2022: $29K · 2023: $669 · 2024: $283 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.84 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $44,573.65 | 2019-2024 | Cequa, Xelpros |
| Shire North American Group INC | $19,697.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $5,227.23 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $3,839.34 | 2019-2024 | Meibomian Gland Evaluator, Lipiflow System Activator (Disposable) |
| Horizon Therapeutics Plc | $1,560.26 | 2021-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $1,464.54 | 2019 | |
| Tearlab Corp | $520.42 | 2022 | |
| Glaukos Corporation | $248.37 | 2019-2025 | Istent Infinite, Idosetr |
| Mallinckrodt Hospital Products INC. | $234.86 | 2021-2022 | |
| Abbvie INC. | $228.85 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Oyster Point Pharma, INC. | $199.57 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $128.59 | 2019-2025 | Clareon, Eysuvis, Hydrus Microstent |
| Sight Sciences, INC. | $128.14 | 2019-2025 | Tearcare System |
| Dompe US, INC. | $107.40 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $97.64 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $77.23 | 2021-2022 | |
| Amgen INC. | $74.21 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $67.63 | 2021-2023 | Dextenza |
| Harrow Eye, LLC | $63.71 | 2025 | Vevye |
| Rxsight INC | $54.20 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.07 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $40.69 | 2024 | Xdemvy |
| Rayner Intraocular Lenses Limited | $31.94 | 2024 | Rayone Aspheric, Rayone Spheric, Rayner Cataract Set 1 |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Aerie Pharmaceuticals, INC. | $15.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Schmit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.